Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 204

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

Open access
Cortellini, Alessio, Buti, Sebastiano, Santini, Daniele, Perrone, Fabiana, Giusti, Raffaele, Tiseo, Marcello, Bersanelli, Melissa, Michiara, Maria, Grassadonia, Antonino, Brocco, Davide, Tinari, Nicola, De Tursi, Michele, Zoratto, Federica, Veltri, Enzo, Marconcini, Riccardo, Malorgio, Francesco, Garufi, Carlo, Russano, Marco, Anesi, Cecilia, Zeppola, Tea, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Antonini Cappellini, Gian Carlo, De Galitiis, Federica, Vitale, Maria Giuseppa, Sabbatini, Roberto, Bracarda, Sergio, Berardi, Rossana, Rinaldi, Silvia, Tudini, Marianna, Silva, Rosa Rita, Pireddu, Annagrazia, Atzori, Francesco, Chiari, Rita, Ricciuti, Biagio, Iacono, Daniela, Migliorino, Maria Rita, Rossi, Antonio, Porzio, Giampiero, Cannita, Katia, Ciciarelli, Valeria, Fargnoli, Maria Concetta, Ascierto, Paolo Antonio, Ficorella, Corrado · 2019 · The Oncologist

Abstract

Background: Patients with a history of autoimmune diseases (AIDs) have not usually been included in clinical trials with immune checkpoint inhibitors. Materials and Methods: Consecutive patients with advanced cancer, treated with anti-programmed death-1 (PD-1) agents, were evaluated according to the presence of pre-existing AIDs. The incidence of immune-related adverse events (irAEs) and clinical outcomes were compared among subgroups. Results: A total of 751 patients were enrolled; median age was 69 years. Primary tumors were as follows: non-small cell lung cancer, 492 (65.5%); melanoma, 159 (21.2%); kidney cancer, 94 (12.5%); and others, 6 (0.8%). Male/female ratio was 499/252. Eighty-five patients (11.3%) had pre-existing AIDs, further differentiated in clinically active (17.6%) and inactive (82.4%). Among patients with pre-existing AIDs, incidence of irAEs of any grade was significantly higher when compared with patients without AIDs (65.9% vs. 39.9%). At multivariate analysis, both inactive (p = .0005) and active pre-existing AIDs (p = .0162), female sex (p = .0004), and Eastern Cooperative Oncology Group Performance Status <2 (p = .0030) were significantly related to a higher incidence of irAEs of any grade. No significant differences were observed regarding grade 3/4 irAEs and objective response rate among subgroups. Pre-existing AIDs were not significantly related with progression-free survival and overall survival. Conclusion: This study quantifies the increased risk of developing irAEs in patients with pre-existing AIDs who had to be treated with anti-PD-1 immunotherapy. Nevertheless, the incidence of grade 3/4 irAEs is not significantly higher when compared with control population. The finding of a greater incidence of irAEs among female patients ranks among the “hot topics” in gender-related differences in immuno-oncology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2018-0618

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 204

Metadata

Authors
Cortellini, A., Buti, S., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Bersanelli, M., Michiara, M., Grassadonia, A., Brocco, D., Tinari, N., De Tursi, M., Zoratto, F., Veltri, E., Marconcini, R., Malorgio, F., Garufi, C., Russano, M., Anesi, C., Zeppola, T., Filetti, M., Marchetti, P., Botticelli, A., Antonini Cappellini, G. C., De Galitiis, F., Vitale, M. G., Sabbatini, R., Bracarda, S., Berardi, R., Rinaldi, S., Tudini, M., Silva, R. R., Pireddu, A., Atzori, F., Chiari, R., Ricciuti, B., Iacono, D., Migliorino, M. R., Rossi, A., Porzio, G., Cannita, K., Ciciarelli, V., Fargnoli, M. C., Ascierto, P. A., & Ficorella, C.
Venue
The Oncologist
Published
2019-02-22
Volume
24
Issue
6
Pages
e327-e337
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W2915650040
Cited by
204
References
12
FWCI
9.70
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. https://app.cochat.ai/papers/10.1634/theoncologist.2018-0618
The paper
Cortellini, A., Buti, S., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Bersanelli, M., Michiara, M., Grassadonia, A., Brocco, D., Tinari, N., De Tursi, M., Zoratto, F., Veltri, E., Marconcini, R., Malorgio, F., Garufi, C., Russano, M., Anesi, C., . . . Ficorella, C. (2019). Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. The Oncologist. https://doi.org/10.1634/theoncologist.2018-0618

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.